

1 Non-invasive Auricular Vagus nerve stimulation for Subarachnoid
2 Hemorrhage (NAVSaH): Protocol for a prospective, triple-blinded,
3 randomized controlled trial

4

5 Anna L Huguenard^{1*}, Gansheng Tan², Gabrielle W Johnson¹, Markus Adamek³, Andrew T Coxon¹, Terrance
6 T Kummer⁴, Joshua W Osbun¹, Ananth K Vellimana¹, David D. Limbrick, Jr.¹, Gregory J Zipfel¹, Peter
7 Brunner^{1,2}, Eric C Leuthardt^{1,2,3}

8

9 ¹ Department of Neurosurgery, Washington University in St. Louis, St. Louis, Missouri, USA

10 ² Department Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA

11 ³ Department of Neuroscience, Washington University in St. Louis, St. Louis, Missouri, USA

12 ⁴ Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA

13

14 * Corresponding Author

15 Email: ahuguenard@wustl.edu (ALH)

16

17

18

19 **Abstract**

20 **Background**

21 Inflammation has been implicated in driving the morbidity associated with subarachnoid hemorrhage (SAH).
22 Despite understanding the important role of inflammation in morbidity following SAH, there is no current
23 effective way to modulate this deleterious response. There is a critical need for a novel approach to
24 immunomodulation that can be safely, rapidly, and effectively deployed in SAH patients. Vagus nerve
25 stimulation (VNS) provides a non-pharmacologic approach to immunomodulation, with prior studies
26 demonstrating VNS can reduce systemic inflammatory markers, and VNS has had early success treating
27 inflammatory conditions such as arthritis, sepsis, and inflammatory bowel diseases. The aim of the Non-
28 invasive Auricular Vagus nerve stimulation for Subarachnoid Hemorrhage (NAVSaH) trial is to translate the
29 use of non-invasive transcutaneous auricular VNS (taVNS) to spontaneous SAH, with our central hypothesis
30 being that implementing taVNS in the acute period following spontaneous SAH attenuates the expected
31 inflammatory response to hemorrhage and curtails morbidity associated with inflammatory-mediated clinical
32 endpoints.

33 **Materials and methods**

34 The overall objectives for the NAHSaH trial are to 1) Define the impact that taVNS has on SAH-induced
35 inflammatory markers in the plasma and cerebrospinal fluid (CSF), 2) Determine whether taVNS following
36 SAH reduces radiographic vasospasm, and 3) Determine whether taVNS following SAH reduces chronic
37 hydrocephalus. Following presentation to a single enrollment site, enrolled SAH patients are randomly
38 assigned twice daily treatment with either taVNS or sham stimulation for the duration of their intensive care
39 unit stay. Blood and CSF are drawn before initiation of treatment sessions, and then every three days during
40 a patient's hospital stay. Primary endpoints include change in the inflammatory cytokine TNF- α in plasma
41 and cerebrospinal fluid between day 1 and day 13, rate of radiographic vasospasm, and rate of requirement
42 for long-term CSF diversion via a ventricular shunt. Secondary outcomes include exploratory analyses of a
43 panel of additional cytokines, number and type of hospitalized acquired infections, duration of external
44 ventricular drain in days, interventions required for vasospasm, continuous physiology data before, during,
45 and after treatment sessions, hospital length of stay, intensive care unit length of stay, and modified Rankin
46 Scale score (mRS) at admission, discharge, and each at follow-up appointment for up to two years following

47 SAH.

48 Discussion

49 Inflammation plays a central role in morbidity following SAH. This NAVSaH trial is innovative because it
50 diverges from the pharmacologic status quo by harnessing a novel non-invasive neuromodulatory approach
51 and its known anti-inflammatory effects to alter the pathophysiology of SAH. The investigation of a new,
52 effective, and rapidly deployable intervention in SAH offers a new route to improve outcomes following SAH.

53 **Trial registration:** Clinical Trials Registered, NCT04557618. Registered on September 21, 2020, and the
54 first patient was enrolled on January 4, 2021

55 **Keywords:** Vagus nerve stimulation, Intracranial aneurysm, Subarachnoid hemorrhage, Inflammation,
56 Vasospasm, Hydrocephalus

57 Introduction

58 Background and rationale

59 Intracranial aneurysms are common, with 3-5% of all adults harboring at least one. The resulting
60 subarachnoid hemorrhage (SAH) from ruptured aneurysms accounts for 5–10% of all strokes worldwide,
61 culminating in a total of 600,000 new cases per year [1]. SAH is a major driver of mortality and morbidity,
62 with 10-25% of patients dying following SAH and an additional 30% of patients suffering permanent disability
63 [2]. While the immediate sequelae of SAH can include risk for re-rupture, elevated intracranial pressure, and
64 acute hydrocephalus, secondary injury is a major driver of morbidity as mediated by early brain injury,
65 cerebral vasospasm, delayed cortical ischemia, and chronic hydrocephalus [3]. Targeting the post-
66 hemorrhage period with the goal of reducing these secondary sequelae from SAH is an important
67 mechanism for improving outcomes in SAH patients.

68 There is growing evidence that systemic and local inflammation may promote aneurysm formation
69 and rupture as well as lead to poorer outcomes following aneurysmal rupture. Following SAH, blood within
70 the subarachnoid space triggers both local, as measured by inflammatory markers in the cerebrospinal fluid
71 (CSF), and systemic inflammatory responses, as measured by inflammatory markers in the blood. Prior work
72 has identified increased cytokines including IL-1 β , IL-4, IL-8, IL-10, IL-18, and IL-33, following SAH in animal
73 [4-7] and human [8-13] studies. Key drivers of SAH-induced inflammation are the cytokines IL-6 and TNF- α .

74 Studies in canine and rabbit models of SAH demonstrate increased rates of vasospasm correlated with

75 expression of IL-6 in the basilar artery [6] and CSF [14], respectively. Work performed in humans reveals
76 elevated IL-6 in the blood [11] and CSF [9,11,15-17] following SAH. In several studies, elevated IL-6 in the
77 CSF was significantly correlated with development of vasospasm [9,16], delayed cortical ischemia [17],
78 chronic hydrocephalus [18,19], and poorer overall outcome [9,11] following SAH. Similarly, studies in rodent
79 [20] and rabbit [21] models of SAH found increased TNF- α was associated with vasospasm. In humans,
80 elevated TNF- α in the blood [22,23] and CSF [8,9,24,25] have been demonstrated following SAH. Elevated
81 TNF- α has been associated with vasospasm [8,9,24], hydrocephalus [8], and poor outcome [8,22].

82 Numerous anti-inflammatory interventions have been trialed in humans to better understand, and
83 eventually target, inflammatory pathways to improve outcomes after SAH [26-29]. In smaller enrollment
84 studies, there was promise of outcome improvement with Cyclosporine A [30,31] and steroids like
85 methylprednisolone [32,33], hydrocortisone [34], and dexamethasone [35]. Other medications demonstrated
86 no impact on overall outcomes, like Clazosentan [36,37], Cilostazol [38], and IL-1 antagonists [39,40]. In
87 several meta-analysis studies looking at groups larger than 1000 patients, Simvastatin [41], Aspirin, non-
88 steroidal anti-inflammatory medications, and thienopyridines [42] all demonstrated no improvement in
89 outcomes. In summary, while some pathway-targeted pharmacological approaches have led to changes in
90 secondary outcomes of vasospasm and delayed cerebral ischemia in clinical trials [37,38], these approaches
91 have failed to produce an effective intervention that reliably improves outcomes in SAH patients. Thus, there
92 is an urgent need to find a novel approach to more globally and meaningfully reduce inflammation in SAH to
93 reduce patient morbidity.

94 Vagus nerve stimulation (VNS) has been studied as a novel method of reducing inflammation.
95 Substantial work has demonstrated that products of infection or injury activate sensory neurons traveling to
96 the brainstem in the vagus nerve [43,44]. The arrival of these incoming signals generates action potentials
97 that travel from the brainstem to the spleen and other organs. This culminates in T cell release of
98 acetylcholine, which interacts with $\alpha 7$ nicotinic acetylcholine receptors ($\alpha 7$ nAChR) on immunocompetent
99 cells to inhibit cytokine release in macrophages [45]. This neural-immunomodulatory circuit, referred to as
100 the “cholinergic anti-inflammatory pathway”, presents opportunities for developing novel therapeutic
101 strategies to treat inflammatory diseases. It has been successfully implemented in models of inflammatory
102 conditions like induced neuroinflammation [46], cerebral ischemia/reperfusion [47], rheumatoid arthritis [48],
103 sepsis [49], and inflammatory bowel diseases [50,51] or colitis [52]. Harnessing its anti-inflammatory effects,
104 VNS has been used in a mouse model of cerebral aneurysms and SAH [53]. In this study, pre-treatment with

105 VNS not only reduced the rupture rate of intracranial aneurysms, but also reduced the grade of hemorrhage
106 if rupture occurred and improved survival and outcome after SAH [53]. There has not been any published
107 work implementing VNS following SAH in humans.

108 Historically, VNS was performed exclusively by surgical cervical neck dissection and placement of a
109 cuff electrode directly around the nerve within the carotid sheath. Alternatively, VNS can be accomplished
110 non-invasively by stimulating the auricular branch of the vagus nerve as it courses through the external ear,
111 obviating the morbidity of a surgical procedure and allowing rapid deployment of the intervention in critically
112 ill patients. The external ear is an ideal target for non-invasive stimulation of the vagus nerve, where the
113 auricular branch travels in the concha of the ear [54]. This transcutaneous auricular approach has
114 demonstrated good efficacy, with minimal morbidity [54,55].

115 Taken together, there is substantial evidence that VNS is an emerging tool to mitigate inflammation,
116 but there is a dearth of understanding on its effects on SAH in humans.

117 **Objectives**

118 Our long-term goal is to translate the use of non-invasive transcutaneous auricular VNS (taVNS) to reduce
119 morbidity and improve outcomes in patients following spontaneous SAH. The overall objectives for the
120 NAVSaH trial in pursuit of achieving this goal are to (i) demonstrate the impact taVNS has on inflammatory
121 markers in the blood and CSF in patients following SAH, and (ii) determine if taVNS reduces the incidence of
122 inflammation-mediated sequelae of SAH by performing a prospective, randomized controlled trial. Our
123 central hypothesis is that implementing taVNS in the acute period following spontaneous SAH will attenuate
124 the expected inflammatory response to hemorrhage and will curtail morbidity associated with inflammatory-
125 mediated clinical endpoints (i.e., vasospasm & hydrocephalus). By pursuing this project, we expect to
126 demonstrate the important role that neuromodulation can play in SAH. More specifically, we expect this work
127 will create the foundation of knowledge for advancing non-invasive taVNS to enable further research to
128 translate this as an established clinical intervention in the future.

129 **Materials and methods**

130 **Trial design**

131 NAVSaH is a prospective, triple-blinded (patient, care team, and outcomes assessor), randomized-control
132 trial to assess superiority of intervention with vagus nerve stimulation following spontaneous subarachnoid

133 hemorrhage compared to standard of care with respect to inflammatory markers in the blood and CSF, rate
134 of radiographic vasospasm, and rate of development of chronic hydrocephalus. Treatment and sham
135 assignments are made with a 1:1 allocation. Figs 1 and 2 represents an overview of the trial design. This
136 protocol manuscript was written in accordance with the Standard Protocol Items: Recommendations for
137 Interventional Trials (SPIRIT) guidelines [56] and the Consolidated Standards of Reporting Trials
138 (CONSORT) statement [57].

139 **Fig 1: SPIRIT schedule of enrollment, interventions, and assessments**

140 **Fig 2: Timeline for enrollment and participation in the NAVSaH clinical trial by participants.**

141 Cerebrospinal fluid (CSF)

142 **Methods: participants, interventions and outcomes**

143 **Study setting**

144 The NAVSaH trial is being conducted at a single center, a tertiary care academic hospital center, Barnes
145 Jewish Hospital/Washington University in St. Louis (St. Louis, MO, USA).

146 **Eligibility criteria**

147 Participants include all individuals who present with a spontaneous subarachnoid hemorrhage, aged >18
148 years old. Exclusion criteria includes traumatic etiology for hemorrhage, negative vascular imaging for
149 aneurysm (CT angiogram or cerebral angiogram), ongoing cancer therapy, ongoing use of an
150 immunomodulating or suppressive medication, sustained bradycardia on arrival with a heart rate < 50 beats
151 per minute for > 5 minutes, implanted pacemaker or other electrical device, current pregnancy, or a positive
152 test for the Covid-19 virus.

153 **Who will take informed consent?**

154 Patients provide written consent for themselves when able. For patients who are unable to provide consent
155 given cognitive impairment from their subarachnoid hemorrhage, then a legally authorized representative
156 can provide written informed consent in conjunction with patient assent (whenever possible). The patient or
157 legally authorized representative are informed about the objectives of the study as well as potential risks and
158 benefits of participation. Documentation of consent is kept in paper format and maintained in a locked and
159 secure storage box by trial staff. Consent is obtained by either a physician member of the research team, or
160 an appropriately trained research coordinator. In all situations, the team member seeking informed consent

161 is not involved in the medical care of the enrollee, to prevent actual or implied bias or compulsion for trial
162 participation.

163 **Additional consent provisions for collection and use of participant data** 164 **and biological specimens**

165 There are no additional consent provisions for specific ancillary studies, however, there is an optional
166 provision in the consent form to allow for use of data collected for future related studies.

167 **Interventions**

168 **Explanation for the choice of comparators**

169 Both arms of the NAVSaH trial will receive standard of care for management of subarachnoid hemorrhage,
170 not limited to intensive care monitoring, treatment of a ruptured aneurysm via endovascular or surgical
171 means as dictated by the physician team, cerebrospinal fluid diversion when considered medically indicated,
172 and repeated imaging studies as deemed necessary by the physician team. Treatment with non-invasive
173 vagus nerve stimulation has been implemented in many other studies, and has a demonstrated safety profile
174 when implemented previously following acute ischemic or hemorrhagic stroke [58]. Sham stimulation, which
175 is delivered as a comparator, involves the placement of ear clips without electrical stimulation has no
176 perceived positive or negative effect on clinical outcome, or foreseeable risk for adverse effects.

177 **Intervention description**

178 Enrolled participants are randomized to one of two study arms and receive either 1) twice daily non-invasive
179 auricular vagus nerve stimulation to the left ear, or 2) sham stimulation involving placement of the ear clips
180 without applied electrical current. Treatment is applied twice daily, similar to other studies applying vagus
181 nerve stimulation to drive reduction in inflammation [59-61]. The electrodes are placed on the left ear,
182 consistent with the typical left-sided cervical placement of invasive vagus nerve stimulators [62], although no
183 evidence indicates laterality in cardiac effects in non-invasive stimulation. An enrolled patient will begin with
184 either taVNS or sham stimulation twice daily during their stay in the intensive care unit while continuous
185 heart rate/rhythm, blood pressure, intracranial pressure, and oxygenation monitoring is in place. Each day,
186 there is one session each morning (between 05:00-10:00) and one each evening (between 16:00-21:00).
187 The initial treatment session occurs during the first treatment block time after informed consent is complete.
188 All patients are fitted with a portable TENS (transcutaneous electrical nerve stimulation) unit connected to
189 two ear clips, applied to the left ear during treatment periods. For VNS treatment, these ear clips are placed

190 along the concha of the ear (Fig 3), with positioning optimized to target the auricular branch of the vagus
191 nerve [61]. Stimulation parameters were selected based on prior studies that sought to maximize vagus
192 somatosensory evoked potentials while avoiding perception of pain [63,64]. Stimulation parameters will be
193 20 minutes duration, frequency of 20 Hz, 250 μ s pulse width, and an intensity of 0.4mA. Sham treatments will
194 involve no electrical current. Treatment sessions with either taVNS or Sham stimulation will end after transfer
195 out of the intensive care unit.

196 **Fig 3: Target for auricular vagus nerve stimulation.** Vagus nerve stimulation is administered by placing
197 the stimulating electrodes along the concha of the ear, where the innervation of the auricular branch of the
198 vagus nerve runs.

199 **Criteria for discontinuing or modifying allocated interventions**

200 The study treatment will be discontinued if a participant meets any of the following criteria: if irritation or
201 redness at the stimulation site occurs, evidence of induced clinically significant changes in heart rate or
202 rhythm, or by participant or legally authorized representative request. In these cases, the treatment sessions
203 will cease, but blood and cerebrospinal fluid draws and recording of clinical outcomes will continue unless by
204 request by the patient or legally authorized representative request.

205 **Strategies to improve adherence to interventions**

206 All treatment sessions occur while the enrolled patient is admitted to the hospital, and in the intensive care
207 unit. Therefore, we anticipate few barriers to adherence with the intervention.

208 **Relevant concomitant care permitted or prohibited during the trial**

209 All medications, procedures, or interventions recommended by the medical team to manage an enrolled
210 patient's subarachnoid hemorrhage will be permitted. The patient will not be permitted to receive any
211 intervention that is associated with a separate clinical trial.

212 **Provisions for post-trial care**

213 There is no anticipated harm and no planned compensation for trial participation. All post-trial care will follow
214 the typical follow-up for patients discharged after subarachnoid hemorrhage (including follow-up imaging or
215 physician office visits). No additional imaging, laboratory studies, or hospital visits are otherwise required due
216 to trial participation alone.

217 **Outcomes**

218 The NAVSaH trial's evaluated end points include: 1) Defining the impact that taVNS has on the SAH-induced

219 inflammatory markers in the plasma and cerebrospinal fluid (CSF), 2) Determining if taVNS following SAH
220 reduces angiographic vasospasm 3) Determining if taVNS following SAH reduces chronic hydrocephalus.
221

222 For assessment of the impact taVNS has on inflammatory makers, blood and CSF is collected prior to the
223 initial treatment session as a baseline, and then every three days during the patient's inpatient hospital stay
224 (CSF collected only when an external ventricular drain is in place). The primary inflammatory marker
225 assessed is TNF- α , although a panel of 13 cytokines is analyzed in an exploratory fashion (IL-1 β , IL-2, IL-4,
226 IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF- α , GM-CSF, and IFN- γ). Differences regarding the local and
227 systemic inflammatory cytokine TNF- α reduction from baseline to day 13 post-treatment will primarily be
228 examined through the interaction of time and treatment effects, with additional exploratory analyses
229 performed for other days.

230
231 To assess angiographic vasospasm, serial vascular imaging studies will be evaluated. In addition to initial
232 diagnostic imaging, patients will undergo a repeat computed tomography or catheter angiogram seven
233 days after admission, per our hospital's standard protocol. Additionally, further vascular imaging will be
234 performed if there is clinical concern per the intensive care or neurosurgical teams for clinical vasospasm or
235 stroke. For both planned and indicated imaging sessions, each vascular imaging study will be reviewed by a
236 trained neurointerventionalist blinded to treatment arm, who will measure and quantify the imaging as it
237 relates to vasospasm as none, mild (< 25% stenosis), moderate (25%–50% stenosis), or severe (> 50%
238 stenosis) narrowing of at least one major intracranial artery, as previously described [65,66].

239
240 To evaluate the rate of chronic hydrocephalus, the primary outcome assessed will be binary (placement of
241 ventricular shunt, versus no shunt placement).

242
243 The trial's secondary end points include: patient demographics (gender, ethnicity, and age), number and
244 type of hospitalized acquired infections, duration of external ventricular drain in days, interventions required
245 for vasospasm (blood pressure augmentation, intraarterial medications, intrathecal medications,
246 endovascular intervention with angioplasty), continuous physiology data (heart rate, blood pressure,
247 respiratory rate, intracranial pressure) before, during, and after treatment sessions, hospital length of stay,
248 intensive care unit length of stay, and modified Rankin Scale score (mRS) at admission, discharge, and each

249 at follow-up appointment for up to two years following SAH.

250 **Participant timeline**

251 The schematic overview of the NAVSaH trial is shown in Fig 2. Study start-up began in July 2020, including
252 protocol development and single institutional review board approval. Trial enrollment began in January 2021,
253 and it is anticipated that enrollment will continue for approximately 4 years from that date. Participants are
254 enrolled in an acute care setting when they present with a spontaneous SAH, with enrollment occurring
255 within 24 hours of arrival to the hospital. Intervention with taVNS or Sham stimulation occurs twice daily while
256 the patient is in the intensive care unit, and discontinues on transfer to lower level of care from ICU. A mRS
257 is assessed at time of hospital admission, at time of discharge, and at all follow-up appointments with the
258 Neurosurgery clinic or Neuroangiography team in the two years following admission by an assessor blinded
259 to treatment arm. Follow-up with the Neurosurgical and Neuroangiography teams follows standard of care,
260 and no additional follow-up appointments are scheduled strictly for the NAVSaH trial.

261 **Sample size**

262 Goal enrollment for the pilot NAVSaH trial is 50 patients, based on power calculations to detect significant
263 differences in inflammatory cytokines, radiographic vasospasm, and chronic hydrocephalus.

264

265 Under a 2-by-2 repeated measures design consisting of two groups of patients, each measured at two time
266 points, our goal is to compare the change across time in the taVNS group to the change across time in the
267 Sham group. Based upon previous work from Koopman et al. [67], we assume our study will observe 1.1
268 standardized inflammatory cytokines mean change difference between the two groups. Using a two-sided,
269 two-sample t-test, assuming both time points have equal variance and there is a weak correlation (i.e., 0.15)
270 between measurement pairs, a sample size of 25 in each group achieves at least 80% power to detect a
271 standardized difference of 1.1 in mean changes, with a significance level (alpha) of 0.05 [68].

272

273 Based upon our preliminary data, we assume this study will observe 25% and 55% severe vasospasm in the
274 taVNS and Sham groups, respectively. Under a design with 2 repeated measurements (i.e., 2 raters),
275 assuming a compound symmetry covariance structure with a Rho of 0.2, at a significance level (alpha) of
276 0.05, a sample size of 25 in each group achieves at least 80% power when the null proportion is 0.55, and
277 the alternative proportion is 0.25 [69-71].

278

279 As previously described, LV et al. [8] studied the relationship between cytokine levels and clinical endpoints
280 in SAH, including hydrocephalus. From their outcomes, we predict a needed enrollment of approximately 50
281 to detect these endpoints. From our own preliminary data, with an incidence of chronic hydrocephalus 0% in
282 treated patients and 28.6% in control (despite grade of hemorrhage), $\alpha = 0.05$ and power = 0.80, the
283 projected sample size to capture that change is approximately 44 patients.

284 **Recruitment**

285 Members of the Neurosurgical team and Intensive Care team identify potential candidates for the NAVSaH
286 trial and notify the research team who conducts formal screening to determine candidacy. Recruitment
287 outside of the hospital, or prior to admission, is not performed.

288 **Assignment of interventions: allocation**

289 **Sequence generation**

290 Participants are randomized 1:1 to receive treatment with taVNS or Sham stimulation. Randomization is via
291 a simple randomization via computer generated random generated numbers, with next-number obscured
292 until after consent is completed and time of patient enrollment into the study.

293 **Concealment mechanism**

294 The computer-generated randomization sequence is concealed, and the treatment group allocation via
295 random number generation occurs only after the patient has been consented and enrolled in the trial.
296 Following assignment of treatment group, treatment arm remains concealed to the patient, medical team,
297 and outcomes assessors.

298 **Implementation**

299 Treatment group allocation is via a simple randomization via computer generated random number
300 assignment (0 vs 1). Patients are enrolled prior to randomization by a member of the research team who
301 goes through the informed consent process with the patient, or their legally authorized representative when
302 appropriate. A single investigator is responsible for entering the patient into the computer system to ascertain
303 the assigned treatment arm.

304 **Assignment of interventions: Blinding**

305 **Who will be blinded**

306 Research team members, who apply the ear clips and set stimulation parameters, are not blinded to
307 treatment arm. The participant, the medical team who dictates all management decisions for the patient's
308 subarachnoid hemorrhage, and outcomes assessors (those who assign modified Rankin scores at
309 admission, discharge, and at each outpatient follow-up appointment) are blinded to treatment arm.
310 Stimulation parameters are sub-sensory, meaning there is no perceived sensation in the setting of
311 stimulation.

312 **Procedure for unblinding if needed**

313 There are no proposed circumstances in which unblinding will be performed. If there are concerns regarding
314 adverse events from the intervention then treatment sessions can be ended prematurely, without revealing
315 treatment group.

316 **Data collection and management**

317 **Plans for assessment and collection of outcomes**

318 Collected data regarding patient clinical presentation, hospital events, clinical outcomes, results from
319 imaging studies, and serial laboratory data will be collected and stored via REDCap. The web-based
320 interface is designed specifically for clinical trials and prospective observational studies. REDCap and the
321 electronic health record will be used for all data collection.

322 **Plans to promote participant retention and complete follow-up**

323 The intervention is only administered during the patient's hospital stay, so there are no foreseeable barriers
324 to retaining participants during the intervention period. Required blood collection is drawn from an indwelling
325 line when available, or is collected at the same time as a patient's otherwise collected blood samples if
326 venipuncture is required to minimize additional needle sticks that may dissuade ongoing participation during
327 the hospital stay. All primary endpoints are collected during the hospital stay, with no foreseeable barriers to
328 obtaining this clinical information. Following discharge, the patient is not required to make additional visits.
329 Some exploratory outcomes are tracked following discharged but will not be part of the primary analysis. Not
330 mandating additional study visits minimizes the burden on enrolled patients, and further encourages
331 retention in the study long-term.

332 **Data management**

333 Data entry input into RedCap undergoes second user validation to confirm data quality. All analysis of
334 continuous variables includes identification of outliers to assess for errors in data collection or reporting.

335 **Confidentiality**

336 During this study, medical history (medical diagnoses, surgical history, current medications), information
337 about a patient's clinical course during hospitalization (medications or procedures performed, radiology
338 exams obtained, and physical exam findings and functional assessments), as well as laboratory data
339 (samples from blood and cerebrospinal fluid) will be assessed. All of the materials collected are for research
340 purposes only, and data will be kept in strict confidence. No identifiable information will be given to anyone
341 without permission from the subject. The consent form includes the informed consent statement required by
342 Washington University for studies involving PHI. Confidentiality will be ensured by use of unique
343 identification codes. Data will be de-identified and stored with an assigned ID number. Data access will be
344 limited to study staff. Data and records will be kept locked and secured, with any computer data password
345 protected. No reference to any individual participant will appear in reports, presentations, or publications that
346 may arise from the study.

347

348 The database will be secured with password protection. The informatics manager will receive only coded
349 information that is entered into the database under those identification numbers. Electronic communication
350 with outside collaborators will involve only unidentifiable information. Additionally, all traceable data from
351 copied medical records will also be removed.

352 **Plans for collection, laboratory evaluation and storage of biological specimens for 353 genetic or molecular analysis in this trial/future use**

354 While blood and cerebrospinal fluid samples are collected in this study, there are no current plans for genetic
355 analysis. In this trial, analysis of biological samples is limited to evaluation of inflammatory cytokines as
356 described previously, which are stored labeled only with the deidentified study ID number. However, the
357 informed consent does include an additional request for approval to allow data and collected biological
358 specimens to be used in future research.

359 **Statistical methods**

360 **Statistical methods for primary and secondary outcomes**

361 The primary outcome of Aim 1 is quantified continuous measures of the plasma and CSF TNF- α collected at
362 two time points, baseline (before treatment) and day 13 after treatment. The taVNS impact on SAH
363 inflammatory markers will be examined via a linear mixed model, where time (i.e., 0- and 13-days post-
364 treatment), treatment (i.e., taVNS vs. Sham), and time-treatment interaction are the fixed effects, and the
365 dependency of measurements clustered within each individual patient will be accounted for via the random
366 effects. Group differences regarding the local and systemic inflammatory cytokines reduction from baseline
367 to day 13 post-treatment will be examined through the interaction of time and treatment effects. Model
368 assumptions will be inspected, and remedy will be applied if necessary. Secondary outcomes involve
369 exploratory analyses of the remainder of the inflammatory markers collected from plasma and CSF.

370

371 The primary outcome of Aim 2 is the highest severity of vasospasm (binary, moderate/severe vs. non
372 moderate/severe) as assessed by measurements performed by a Neurointerventionalist. A mixed effect
373 logistic regression model will be used to examine the taVNS and Sham group difference regarding the
374 severity of vasospasm. A generalized estimating equation (GEE) approach will be used to estimate the
375 model parameters assuming a compound symmetry covariance structure, given there might be a possible
376 unknown correlation between observed outcomes within the same patient. For other secondary clinical
377 metrics related to vasospasm, to detect treatment group differences, based upon the distribution of data,
378 independent t-tests or Wilcoxon–Mann–Whitney tests will be performed for continuous variables, and Chi-
379 square tests or Fisher exact tests will be performed for categorical variables.

380

381 The primary outcome of Aim 3 is binary (i.e., shunt vs. non-shunt) and the secondary outcome of Aim 3 is
382 continuous (i.e., the duration of external ventricular drainage). To detect the treatment group difference, a
383 2x2 contingency table and Chi-square test will be used for the binary outcome, and an independent t-test will
384 be used for the continuous outcome.

385 **Interim analyses**

386 The principal investigators or study staff will review all data collection forms on an ongoing basis for data
387 completeness and accuracy as well as protocol compliance. See Table 1 for data type, frequency of review,
388 and reviewer. A statement reflecting the results of the ongoing data review will also be incorporated into the
389 Annual Report for the Independent Monitor.

390

391 The Independent Monitor is appointed to monitor the conduct of the study and subject safety by periodically
392 reviewing data from the study. The Independent Monitor will oversee the overall safety of the study subjects
393 by protecting them from avoidable harm. The Independent Monitor will review adverse events and other
394 relevant study data and will make recommendations regarding continuation of the study to the Principal
395 Investigators. The Principal Investigators will agree to follow the recommendation of the Independent
396 Monitor. This may include termination or suspension of enrollment of the study at any time if it becomes
397 necessary to protect the best interests of the study subjects as advised by the Independent Monitor. If
398 suspicion of an unacceptable risk to participants arises during the conduct of the study, the Independent
399 Monitor, Principal Investigators, institutional review board (IRB), and/or NIH may choose to suspend
400 enrollment until the risk is assessed and a determination is made about the risk. If unacceptable risk is
401 confirmed, the study will be terminated. Decisions to suspend or terminate will be communicated to the IRB.
402 At the time of enrollment suspension or termination a determination will be made about safety follow up
403 assessments required for previously enrolled subjects. The Principal Investigators will notify enrolled
404 subjects, as appropriate, of new information and/or safety follow up assessments as required.
405 Circumstances that may warrant termination or suspension include, but are not limited to: 1) Determination
406 of unexpected, significant, or unacceptable risk to participants, 2) Demonstration of efficacy that would
407 warrant stopping, 3) Insufficient compliance to protocol requirements, 4) Data that are not sufficiently
408 complete and/or evaluable, 5) Determination that the primary endpoint has been met, 6) Determination of
409 futility. The study may resume once concerns about safety, protocol compliance, and data quality are
410 addressed, and satisfy the IRB, Independent Monitor, and NIH.

411 **Methods for additional analyses (e.g. subgroup analyses)**

412 To evaluate for effect of grade of hemorrhage (high grade with a Hunt and Hess Score ≥ 3 , versus low
413 grade), the interaction between assigned treatment and the subgroup factor in a linear model will be tested
414 (significance level of $P < 0.017$). The model will include a main effect for treatment, subgroup factor, and an
415 interaction between subgroup and treatment. Secondary outcomes will also be assessed in similar models.

416 **Methods in analysis to handle protocol non-adherence and any statistical methods** 417 **to handle missing data**

418 High levels of missing data for the outcomes of interest are not expected because these are readily
419 available, documented in medical records as part of the standard of medical care for SAH, and are

420 ascertained during the patient's primary hospital admission. Should there be high rates of participant attrition
421 in the trial, baseline characteristics and available information on the hospital course will be reviewed and
422 compared to participants who do not withdraw from participation to assess for any differences in those who
423 withdraw and those who do not.

424 **Plans to give access to the full protocol, participant level-data and statistical code**

425 A dataset with group-level, de-identified clinical data and participant-level de-identified laboratory data in
426 accordance with the Health Insurance Portability and Accountability Act (HIPAA), as well as statistical code
427 used for analyses and will be made available upon reasonable request. The team will comply with the clinical
428 trial information dissemination expectations of the NIH policy and FDA/DHHS Final Rule to register and
429 submit summary results at ClinicalTrials.gov. Consistent with the terms and conditions of NIH funding, we
430 will ensure the submission and updating of registration and results information for this clinical trial in the
431 timeframes established by the Final Rule.

432 **Oversight and monitoring**

433 **Composition of the coordinating center and trial steering committee**

434 This is a single-center study. There are no other sites participating in the study and there is no need for a
435 separate administrative or data coordinating center. This center's study team will recruit and enroll study
436 participants under the delegation and supervision of the site's Principal Investigators from our Washington
437 University School of Medicine Barnes Jewish Hospital's patient population.

438

439 The research team is comprised of senior investigators in the Departments of Neurosurgery, Biomedical
440 Engineering, and Neurology, who have expertise in the fields of subarachnoid hemorrhage,
441 neuroinflammation, electrical stimulation, and clinical trials. The team's responsibilities include assessment
442 of trial enrollment progress, overall supervision of the trial, and periodic review of the progress of the study to
443 review safety data.

444

445 The lead principal investigator is responsible for overseeing the collection and analysis of data, as well as
446 supervising additional team members who are responsible for identifying potential participants, consenting
447 and enrolling patients, and delivering all treatment sessions.

448

449 Communication is facilitated with weekly 1-hour laboratory group meetings where working issues are
450 reviewed, and any difficulties with the technology, data acquisition, transfer, and analysis are addressed. In
451 addition, every week, there is a 2-hour scientific review of the project work. The principal investigators and
452 research team attend these meetings routinely. In addition, an administrative review meeting for budget and
453 grant administration will be undertaken every 3-4 months.

454 **Composition of the data monitoring committee, its role and reporting structure**

455 An Independent Monitor who is a Neurosurgical faculty at Washington University who is not associated with
456 this research project and thus works independently of the PI, research team, and funding agencies has been
457 assigned to provide additional periodic review of subject enrollment, clinical endpoints/outcomes, laboratory
458 endpoints, and all reported adverse events. This individual is not a part of the key personnel involved in the
459 study, and is qualified to review the patient safety data generated by this study because of their expertise in
460 the areas of Neurosurgery and Neurology.

461 **Adverse event reporting and harms**

462 An adverse event (AE) is any untoward medical occurrence in a subject during participation in the clinical
463 study or with use of the experimental agent being studied. An adverse finding can include a sign, symptom,
464 abnormal assessment (laboratory test value, vital signs, electrocardiogram finding, etc.), or any combination
465 of these.

466 A serious adverse event (SAE) is any adverse event that results in one or more of the following outcomes:

- 467 • Death
- 468 • A life-threatening event
- 469 • Inpatient hospitalization or prolongation of existing hospitalization
- 470 • A persistent or significant disability/incapacity
- 471 • A congenital anomaly or birth defect
- 472 • An important medical event based upon appropriate medical judgment

473 SAEs that are unanticipated, serious, and possibly related to the study intervention will be reported to the
474 Independent Monitor and IRB in accordance with requirements.

- 475 • Unexpected fatal or life-threatening AEs related to the intervention will be reported to the NIH
476 Program Officer within 7 days. Other serious and unexpected AEs related to the intervention will be
477 reported to the NIH Program Officer within 15 days.

- 478 • Anticipated or unrelated SAEs will be handled in a less urgent manner but will be reported to the
479 Independent Monitor, IRB, NIH, and other oversight organizations in accordance with their
480 requirements. In the annual AE summary, the Independent Monitor Report will state that they have
481 reviewed all AE reports.

482 **Frequency and plans for auditing trial conduct**

483 **Table 1:** Frequency and personnel for trial conduct auditing

Data type	Frequency of review	Reviewer
Subject accrual (including compliance with protocol enrollment criteria)	Quarterly	PI, Independent Monitor
Status of all enrolled subjects, as of date of reporting	Quarterly	PI, Independent Monitor
Clinical Endpoints/Outcomes Data	Quarterly	PI, Independent Monitor
Laboratory Endpoints	Quarterly	PI, Independent Monitor
AEs and rates	Quarterly	PI, Independent Monitor
SAEs	Per occurrence	PI, Independent Monitor, NIH

484

485 **Plans for communicating important protocol amendments to relevant parties (e.g.** 486 **trial participants, ethical committees)**

487 All protocol amendments will be reviewed by the study investigators, Principal Investigators, and the
488 Washington University IRB committee. This includes main protocol amendments, revisions of any consent
489 paperwork, and continuing reviews. Any protocol amendments that impact enrolled patients will be
490 communicated to patients as deemed appropriate per review and recommendations by the IRB and
491 Independent Monitor.

492 **Dissemination plans**

493 The Principal Investigators of the clinical trial will comply with the clinical trial information dissemination
494 expectations of the NIH policy and FDA/DHHS Final Rule to register and submit summary results at
495 ClinicalTrials.gov. Consistent with the terms and conditions of NIH funding, we will ensure the submission

496 and updating of registration and results information for this clinical trial in the timeframes established by the
497 Final Rule. Registration and results reporting in ClinicalTrials.gov will be completed within the following
498 timeframes:

- 499 • Registration of the trial at ClinicalTrials.gov no later than 21 days after enrolling the first participant.
- 500 • All submitted information will be updated at least once a year.
- 501 • Any apparent errors, deficiencies, and/or inconsistencies identified by NIH as part of the quality
502 control review process and any other errors identified will be addressed by the responsible party.
- 503 • Corrections to submitted information will be made within 15 days for registration information and 25
504 days for results information.
- 505 • Trial results will be submitted no later than one year after the primary completion date.

506

507 Informed Consent Documents for the clinical trial will include a specific statement relating to posting of
508 clinical trial information at ClinicalTrials.gov. The Washington University IRB has template language
509 explaining that the study will be posted on ClinicalTrials.gov that investigators are required to include in the
510 consent document for the trial. The Principal Investigators will work closely to ensure that clinical trial
511 registration and reporting occurs in compliance with NIH policies and work together to facilitate the process
512 of registration and results reporting to ClinicalTrials.gov in a timely manner, in keeping within the required
513 timeframes. Once data collection is complete, we will work with our statistician to prepare and submit trial
514 results no later than one year after the primary completion date.

515

516 The results of the clinical trial will be disseminated to the public through peer-reviewed publication.
517 Publication will be sought through open access publication to facilitate broad access to the trial's findings.
518 Authorship in all resulting publications will be assigned according to the International Committee of Medical
519 Journal Editors guidelines

520 **Discussion**

521 The NAVSaH trial aims to target the deleterious inflammatory response following spontaneous SAH through
522 use of a novel non-invasive neuromodulatory approach with vagus nerve stimulation. In this single-institution,
523 triple-blinded, randomized controlled clinical trial, the investigators aim to evaluate the efficacy of this
524 intervention on inflammatory markers in the blood and cerebrospinal fluid, and on key clinical endpoints

525 including vasospasm, hydrocephalus, and functional outcome. The cumulative result of the proposed project
526 would be both a biological and clinical validation that taVNS can significantly alter SAH-induced central
527 inflammation and its associated clinical comorbidities, with substantial potential to improve the considerable
528 morbidity associated with SAH. This trial will provide a critical foundation of knowledge to build upon, with
529 future studies projected to more deeply understand the mechanism that links ear stimulation to
530 immunomodulation and the stimulation parameters that best optimize the clinical effect.

531 **Supporting Information**

532 **S1 File** Spirit 2013 Checklist

533

534 **Trial status**

535 The clinical trial (protocol v1.12 dated February 09, 2022) began recruitment in December, 2020, and
536 enrollment will take place over 4 years with an estimated enrolment end date of December, 2024, with two
537 year-follow up results completed in December 2026.

538

539 **Abbreviations**

540	AE	adverse event
541	CSF	cerebrospinal fluid
542	IRB	institutional review board
543	NAVSaH	Non-invasive Auricular Vagus nerve stimulation for Subarachnoid Hemorrhage
544	NIH	National Institutes of Health
545	PI	principal investigator
546	SAE	serious adverse event
547	SAH	subarachnoid hemorrhage
548	taVNS	transcutaneous auricular vagus nerve stimulation
549	VNS	vagus nerve stimulation

550

551 **Authors' contributions**

552 AH, PB, DL, and EL conceived of, and designed the study. AH, GT, GJ, MA, AC, PB, and EL participated in
553 data acquisition and analysis. AH, GT, MA, TK, JO, AV, DL, GZ, PB and EL participated in interpretation of

554 data. AH, PB, and EL contributed to the drafting and significant revision of the manuscript. All authors
555 approved the submitted version and agree to the accuracy and integrity of this work.

556 **Funding**

557 This study was supported by the NIH/NINDS under Award Number 1R21NS128307 (to ECL, PB, and GJZ),
558 The American Association of Neurological Surgeons Robert J. Dempsey, MD, Cerebrovascular Resident
559 Research Award (to ALH), The Aneurysm and AVM Foundation Cerebrovascular Research Grant (to ALH),
560 and Just-In-Time (JIT) Core Usage Funding Program from the Washington University Institute of Clinical and
561 Translational Sciences (to ALH and ECL). The funders had no role in the design and conduct of the study,
562 the collection, management, analysis, and interpretation of the data, or the preparation, review, approval of
563 the manuscript, or decision to submit the manuscript for publication.

564 **Name and contact for trial sponsor**

565 Anna Huguenard, MD
566 Email: ahuguenard@wustl.edu
567 Washington University in St. Louis

568 **Role of the sponsor**

569 For this study, all decisions regarding the design of the study; the collection, management, analysis, and
570 interpretation of data, writing of results; and submissions for publication will be at the discretion of the
571 principal investigator and research team, which includes the sponsor. The funding agencies will not
572 contribute to, nor have authority, over any of these activities.

573 **Availability of data and materials**

574 The lead principal investigator and other members of the research team will have full, unrestricted access to
575 and be responsible for the final dataset. Following publication of the primary and secondary results, group-
576 level, de-identified clinical data and participant-level de-identified laboratory data in accordance with the
577 Health Insurance Portability and Accountability Act (HIPAA), as well as statistical code used for analyses and
578 will be made available upon reasonable request.

579 **Ethics approval and consent to participate**

580 The Washington University Institutional Review Board reviewed and approved the protocol for this trial. In
581 the case of protocol modifications during the trial, approval will be sought from the institutional review board.
582 Written informed consent is obtained from all patients, or their legally authorized guardian in the event the
583 patient is incapacitated from providing their own consent, prior to study enrollment.

584 **Consent for publication**

585 This manuscript contains no personal identifying information, clinical details, or images that require prior
586 consent for publication. There is no intention of reporting identifying patient information when publishing trial
587 results. Participation information materials and informed consent form are available from the corresponding
588 author upon request.

589 **Competing interests**

590 ALH and ECL hold equity in the company Aurenar, LLC. ECL also has stock ownership in Neuroolutions,
591 Face to Face Biometrics, Caeli Vascular, Acera, Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev,
592 Inflexion Vascular, Cordance Medical, Silent Surgical, and Petal Surgical. He is a consultant for E15,
593 Neuroolutions, Inc., Petal Surgical. Washington University owns equity in Neuroolutions. The COI as it relates
594 to this trial has been managed by Washington University.

595 **References**

- 596 1. Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early
597 case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol.* 2009;8:
598 355–369. doi:10.1016/S1474-4422(09)70025-0
- 599 2. Krzyżewski RM, Kliś KM, Kwinta BM, Stachura K, Guzik TJ, Gaśowski J. High Leukocyte Count and
600 Risk of Poor Outcome After Subarachnoid Hemorrhage: A Meta-Analysis. *World Neurosurg.*
601 2020;135: e541–e547. doi:10.1016/j.wneu.2019.12.056
- 602 3. Connolly ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines
603 for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare
604 professionals from the American Heart Association/american Stroke Association. *Stroke; a journal of*
605 *cerebral circulation.* Lippincott Williams & Wilkins Hagerstown, MD; 2012. pp. 1711–1737.
606 doi:10.1161/STR.0b013e3182587839
- 607 4. Huang Q, Wang G, Hu Y-L, Liu J-X, Yang J, Wang S, et al. Study on the expression and mechanism
608 of inflammatory factors in the brain of rats with cerebral vasospasm. *Eur Rev Med Pharmacol Sci.*
609 2017;21: 2887–2894.

- 610 5. Sun Q, Wu W, Hu Y-C, Li H, Zhang D, Li S, et al. Early release of high-mobility group box 1 (HMGB1)
611 from neurons in experimental subarachnoid hemorrhage in vivo and in vitro. *J Neuroinflammation*.
612 *BioMed Central*; 2014;11: 106–17. doi:10.1186/1742-2094-11-106
- 613 6. Aihara Y, Kasuya H, Onda H, Hori T, Takeda J. Quantitative analysis of gene expressions related to
614 inflammation in canine spastic artery after subarachnoid hemorrhage. *Stroke*. Lippincott Williams &
615 Wilkins; 2001;32: 212–217. doi:10.1161/01.str.32.1.212
- 616 7. Wang Y, Zhong M, Tan X-X, Yang Y-J, Chen W-J, Liu W, et al. Expression change of interleukin-8
617 gene in rabbit basilar artery after subarachnoid hemorrhage. *Neurosci Bull. Shanghai Institutes for*
618 *Biological Sciences, Chinese Academy of Sciences*; 2007;23: 151–155. doi:10.1007/s12264-007-
619 0022-1
- 620 8. Lv S-Y, Wu Q, Liu J-P, Shao J, Wen L-L, Xue J, et al. Levels of Interleukin-1 β , Interleukin-18, and
621 Tumor Necrosis Factor- α in Cerebrospinal Fluid of Aneurysmal Subarachnoid Hemorrhage Patients
622 May Be Predictors of Early Brain Injury and Clinical Prognosis. *World Neurosurg*. 2018;111: e362–
623 e373. doi:10.1016/j.wneu.2017.12.076
- 624 9. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schütt S, et al. Inflammatory cytokines in
625 subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral
626 arteries. *J Neurol Neurosurg Psychiatr. BMJ Publishing Group Ltd*; 2001;70: 534–537.
627 doi:10.1136/jnnp.70.4.534
- 628 10. Nam DH, Kim JS, Hong SC, Lee WH, Lee JI, Shin HJ, et al. Expression of interleukin-1 beta in
629 lipopolysaccharide stimulated monocytes derived from patients with aneurysmal subarachnoid
630 hemorrhage is correlated with cerebral vasospasm. *Neurosci Lett*. 2001;312: 41–44.
631 doi:10.1016/s0304-3940(01)02194-2
- 632 11. Al-Tamimi YZ, Bhargava D, Orsi NM, Teraifi A, Cummings M, Ekbote UV, et al. Compartmentalisation
633 of the inflammatory response following aneurysmal subarachnoid haemorrhage. *Cytokine*. 2019;123:
634 154778. doi:10.1016/j.cyto.2019.154778
- 635 12. Chaudhry SR, Kahlert UD, Kinfe TM, Lamprecht A, Niemelä M, Hänggi D, et al. Elevated Systemic
636 IL-10 Levels Indicate Immunodepression Leading to Nosocomial Infections after Aneurysmal

- 637 Subarachnoid Hemorrhage (SAH) in Patients. *Int J Mol Sci. Multidisciplinary Digital Publishing*
638 *Institute*; 2020;21: 1569. doi:10.3390/ijms21051569
- 639 13. Gong J, Zhu Y, Yu J, Jin J, Chen M, Liu W, et al. Increased serum interleukin-33 concentrations
640 predict worse prognosis of aneurysmal subarachnoid hemorrhage. *Clin Chim Acta*. 2018;486: 214–
641 218. doi:10.1016/j.cca.2018.08.011
- 642 14. Croci D, Nevzati E, Danura H, Schöpf S, Fandino J, Marbacher S, et al. The relationship between IL-
643 6, ET-1 and cerebral vasospasm, in experimental rabbit subarachnoid hemorrhage. *J Neurosurg Sci*.
644 2019;63: 245–250. doi:10.23736/S0390-5616.16.03876-5
- 645 15. Vlachogiannis P, Hillered L, Khalil F, Enblad P, Ronne-Engström E. Interleukin-6 Levels in
646 Cerebrospinal Fluid and Plasma in Patients with Severe Spontaneous Subarachnoid Hemorrhage.
647 *World Neurosurg*. 2019;122: e612–e618. doi:10.1016/j.wneu.2018.10.113
- 648 16. Ni W, Gu YX, Song DL, Leng B, Li PL, Mao Y. The relationship between IL-6 in CSF and occurrence
649 of vasospasm after subarachnoid hemorrhage. *Acta Neurochir Suppl. Springer, Vienna*; 2011;110:
650 203–208. doi:10.1007/978-3-7091-0353-1_35
- 651 17. Ridwan S, Grote A, Simon M. Interleukin 6 in cerebrospinal fluid is a biomarker for delayed cerebral
652 ischemia (DCI) related infarctions after aneurysmal subarachnoid hemorrhage. *Sci Rep. Nature*
653 *Publishing Group*; 2021;11: 12–10. doi:10.1038/s41598-020-79586-3
- 654 18. Wostrack M, Reeb T, Martin J, Kehl V, Shiban E, Preuss A, et al. Shunt-dependent hydrocephalus
655 after aneurysmal subarachnoid hemorrhage: the role of intrathecal interleukin-6. *Neurocrit Care*.
656 *Springer US*; 2014;21: 78–84. doi:10.1007/s12028-014-9991-x
- 657 19. Lenski M, Biczok A, Hüge V, Forbrig R, Briegel J, Tonn J-C, et al. Role of Cerebrospinal Fluid
658 Markers for Predicting Shunt-Dependent Hydrocephalus in Patients with Subarachnoid Hemorrhage
659 and External Ventricular Drain Placement. *World Neurosurg*. 2019;121: e535–e542.
660 doi:10.1016/j.wneu.2018.09.159

- 661 20. Chung C-L, Wu C-H, Huang Y-H, Wu S-C, Chai C-Y, Tsai H-P, et al. Blocking Hepatoma-Derived
662 Growth Factor Attenuates Vasospasm and Neuron Cell Apoptosis in Rats Subjected to Subarachnoid
663 Hemorrhage. *Transl Stroke Res.* Springer US; 2021;; 1–11. doi:10.1007/s12975-021-00928-y
- 664 21. Lin C, Zhao Y, Wan G, Zhu A, Wang H. Effects of simvastatin and taurine on delayed cerebral
665 vasospasm following subarachnoid hemorrhage in rabbits. *Exp Ther Med.* Spandidos Publications;
666 2016;11: 1355–1360. doi:10.3892/etm.2016.3082
- 667 22. Chou SH-Y, Feske SK, Atherton J, Konigsberg RG, De Jager PL, Du R, et al. Early elevation of
668 serum tumor necrosis factor- α is associated with poor outcome in subarachnoid hemorrhage. *J*
669 *Investig Med.* BMJ Publishing Group Limited; 2012;60: 1054–1058.
670 doi:10.2310/JIM.0b013e3182686932
- 671 23. Fragata I, Bustamante A, Penalba A, Ferreira P, Nunes AP, Canhão P, et al. TNF-R1 Correlates with
672 Cerebral Perfusion and Acute Ischemia Following Subarachnoid Hemorrhage. *Neurocrit Care.*
673 Springer US; 2020;33: 679–687. doi:10.1007/s12028-020-01082-3
- 674 24. Wu W, Guan Y, Zhao G, Fu X-J, Guo T-Z, Liu Y-T, et al. Elevated IL-6 and TNF- α Levels in
675 Cerebrospinal Fluid of Subarachnoid Hemorrhage Patients. *Mol Neurobiol.* Springer US; 2016;53:
676 3277–3285. doi:10.1007/s12035-015-9268-1
- 677 25. Xie X, Wu X, Cui J, Li H, Yan X. Increase ICAM-1 and LFA-1 expression by cerebrospinal fluid of
678 subarachnoid hemorrhage patients: involvement of TNF- α . *Brain Res.* 2013;1512: 89–96.
679 doi:10.1016/j.brainres.2013.03.041
- 680 26. Provencio JJ, Vora N. Subarachnoid hemorrhage and inflammation: bench to bedside and back.
681 Roos KL, Worrall BB, editors. *Semin Neurol.* Copyright © 2005 by Thieme Medical Publishers, Inc.,
682 333 Seventh Avenue, New York, NY 10001, USA; 2005;25: 435–444. doi:10.1055/s-2005-923537
- 683 27. Chou SH-Y. Inflammation, Cerebral Vasospasm, and Brain Injury in Subarachnoid Hemorrhage-A
684 Shifting Paradigm and a New Beginning. *Crit Care Med.* 2018;46: 1883–1885.
685 doi:10.1097/CCM.0000000000003373

- 686 28. Lucke-Wold BP, Logsdon AF, Manoranjan B, Turner RC, McConnell E, Vates GE, et al. Aneurysmal
687 Subarachnoid Hemorrhage and Neuroinflammation: A Comprehensive Review. *Int J Mol Sci.*
688 *Multidisciplinary Digital Publishing Institute*; 2016;17: 497. doi:10.3390/ijms17040497
- 689 29. de Oliveira Manoel AL, Macdonald RL. Neuroinflammation as a Target for Intervention in
690 Subarachnoid Hemorrhage. *Front Neurol. Frontiers*; 2018;9: 292. doi:10.3389/fneur.2018.00292
- 691 30. Manno EM, Gress DR, Ogilvy CS, Stone CM, Zervas NT. The safety and efficacy of cyclosporine A in
692 the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: a pilot
693 study. *Neurosurgery*. 1997;40: 289–293. doi:10.1097/00006123-199702000-00010
- 694 31. Ryba M, Pastuszko M, Iwanska K, Bidzinski J, Dziewiecki C. Cyclosporine A prevents neurological
695 deterioration of patients with SAH--a preliminary report. *Acta Neurochir (Wien)*. Springer-Verlag;
696 1991;112: 25–27. doi:10.1007/bf01402450
- 697 32. Chyatte D, Fode NC, Nichols DA, Sundt TM. Preliminary report: effects of high dose
698 methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after
699 aneurysmal subarachnoid hemorrhage. *Neurosurgery*. 1987;21: 157–160. doi:10.1227/00006123-
700 198708000-00004
- 701 33. Gomis P, Graftieaux JP, Sercombe R, Hettler D, Scherpereel B, Rousseaux P. Randomized, double-
702 blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid
703 hemorrhage. *J Neurosurg. American Association of Neurological Surgeons*; 2010;112: 681–688.
704 doi:10.3171/2009.4.JNS081377
- 705 34. Hashi K, Takakura K, Sano K, Ohta T, Saito I, Okada K. [Intravenous hydrocortisone in large doses in
706 the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage--results of
707 a multi-center controlled double-blind clinical study]. *No To Shinkei*. 1988;40: 373–382.
- 708 35. Mohny N, Williamson CA, Rothman E, Ball R, Sheehan KM, Pandey AS, et al. A Propensity Score
709 Analysis of the Impact of Dexamethasone Use on Delayed Cerebral Ischemia and Poor Functional
710 Outcomes After Subarachnoid Hemorrhage. *World Neurosurg*. 2018;109: e655–e661.
711 doi:10.1016/j.wneu.2017.10.051

- 712 36. Fujimura M, Joo J-Y, Kim J-S, Hatta M, Yokoyama Y, Tominaga T. Preventive Effect of Clazosentan
713 against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in
714 Japanese and Korean Patients. *Cerebrovasc Dis. Karger Publishers*; 2017;44: 59–67.
715 doi:10.1159/000475824
- 716 37. Shen J, Pan J-W, Fan Z-X, Xiong X-X, Zhan R-Y. Dissociation of vasospasm-related morbidity and
717 outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-
718 analysis of randomized controlled trials. *J Neurosurg. American Association of Neurological
719 Surgeons*; 2013;119: 180–189. doi:10.3171/2013.3.JNS121436
- 720 38. Senbokuya N, Kinouchi H, Kanemaru K, Ohashi Y, Fukamachi A, Yagi S, et al. Effects of cilostazol
721 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective,
722 randomized, open-label blinded end point trial. *J Neurosurg. American Association of Neurological
723 Surgeons*; 2013;118: 121–130. doi:10.3171/2012.9.JNS12492
- 724 39. Galea J, Ogungbenro K, Hulme S, Patel H, Scarth S, Hoadley M, et al. Reduction of inflammation
725 after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid
726 hemorrhage: results of the Subcutaneous Interleukin-1Ra in SAH (SCIL-SAH) study. *J Neurosurg.
727 American Association of Neurological Surgeons*; 2018;128: 515–523. doi:10.3171/2016.9.JNS16615
- 728 40. Singh N, Hopkins SJ, Hulme S, Galea JP, Hoadley M, Vail A, et al. The effect of intravenous
729 interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid
730 haemorrhage: a phase II randomised controlled trial. *J Neuroinflammation. BioMed Central*; 2014;11:
731 1–8. doi:10.1186/1742-2094-11-1
- 732 41. Liu H, Xu X. Effect of simvastatin in patients with aneurysmal subarachnoid hemorrhage: A
733 systematic review and meta-analysis. *Am J Emerg Med*. 2017;35: 1940–1945.
734 doi:10.1016/j.ajem.2017.09.001
- 735 42. Mees SD, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy for aneurysmal subarachnoid
736 haemorrhage. Cochrane Stroke Group, editor. *Cochrane Database of Systematic Reviews*. John
737 Wiley & Sons, Ltd; 2007;54: 872. doi:10.1002/14651858.CD006184.pub2

- 738 43. Andersson U, Tracey KJ. Reflex principles of immunological homeostasis. *Annu Rev Immunol*.
739 Annual Reviews; 2012;30: 313–335. doi:10.1146/annurev-immunol-020711-075015
- 740 44. Pavlov VA, Tracey KJ. Neural regulation of immunity: molecular mechanisms and clinical translation.
741 *Nat Neurosci*. 2017;20: 156–166. doi:10.1038/nn.4477
- 742 45. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor
743 alpha7 subunit is an essential regulator of inflammation. *Nature*. Nature Publishing Group; 2003;421:
744 384–388. doi:10.1038/nature01339
- 745 46. Meneses G, Bautista M, Florentino A, Díaz G, Acero G, Besedovsky H, et al. Electric stimulation of
746 the vagus nerve reduced mouse neuroinflammation induced by lipopolysaccharide. *J Inflamm (Lond)*.
747 *BioMed Central*; 2016;13: 33. doi:10.1186/s12950-016-0140-5
- 748 47. Zhao X-P, Zhao Y, Qin X-Y, Wan L-Y, Fan X-X. Non-invasive Vagus Nerve Stimulation Protects
749 Against Cerebral Ischemia/Reperfusion Injury and Promotes Microglial M2 Polarization Via
750 Interleukin-17A Inhibition. *J Mol Neurosci*. Springer US; 2019;67: 217–226. doi:10.1007/s12031-018-
751 1227-7
- 752 48. Koopman FA, van Maanen MA, Vervoordeldonk MJ, Tak PP. Balancing the autonomic nervous
753 system to reduce inflammation in rheumatoid arthritis. *J Intern Med*. 2017;282: 64–75.
754 doi:10.1111/joim.12626
- 755 49. Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas-Ballina M, et al.
756 Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and
757 improves survival in murine sepsis. *Crit Care Med*. 2007;35: 2762–2768.
758 doi:10.1097/01.CCM.0000288102.15975.BA
- 759 50. Marshall R, Taylor I, Lahr C, Abell TL, Espinoza I, Gupta NK, et al. Bioelectrical Stimulation for the
760 Reduction of Inflammation in Inflammatory Bowel Disease. *Clin Med Insights Gastroenterol*. SAGE
761 PublicationsSage UK: London, England; 2015;8: 55–59. doi:10.4137/CGast.S31779

- 762 51. Sinniger V, Pellissier S, Fauvelle F, Trocmé C, Hoffmann D, Vercueil L, et al. A 12-month pilot study
763 outcomes of vagus nerve stimulation in Crohn's disease. *Neurogastroenterol Motil.* John Wiley &
764 Sons, Ltd; 2020;32: e13911. doi:10.1111/nmo.13911
- 765 52. Chen X, He X, Luo S, Feng Y, Liang F, Shi T, et al. Vagus Nerve Stimulation Attenuates Cerebral
766 Microinfarct and Colitis-induced Cerebral Microinfarct Aggravation in Mice. *Front Neurol.* Frontiers;
767 2018;9: 798. doi:10.3389/fneur.2018.00798
- 768 53. Suzuki T, Takizawa T, Kamio Y, Qin T, Hashimoto T, Fujii Y, et al. Noninvasive Vagus Nerve
769 Stimulation Prevents Ruptures and Improves Outcomes in a Model of Intracranial Aneurysm in Mice.
770 *Stroke.* Lippincott Williams & Wilkins Hagerstown, MD; 2019;5: STROKEAHA118023928.
771 doi:10.1161/STROKEAHA.118.023928
- 772 54. Kaniusas E, Kampusch S, Tittgemeyer M, Panetsos F, Gines RF, Papa M, et al. Current Directions in
773 the Auricular Vagus Nerve Stimulation II - An Engineering Perspective. *Front Neurosci.* 2019;13: 772.
774 doi:10.3389/fnins.2019.00772
- 775 55. Kaniusas E, Kampusch S, Tittgemeyer M, Panetsos F, Gines RF, Papa M, et al. Current Directions in
776 the Auricular Vagus Nerve Stimulation I - A Physiological Perspective. *Front Neurosci.* 2019;13: 854.
777 doi:10.3389/fnins.2019.00854
- 778 56. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013
779 statement: defining standard protocol items for clinical trials. 2013. pp. 200–207. doi:10.7326/0003-
780 4819-158-3-201302050-00583
- 781 57. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting
782 of pragmatic trials: an extension of the CONSORT statement. *BMJ.* 2008;337: a2390.
783 doi:10.1136/bmj.a2390
- 784 58. Arsava EM, Topcuoglu MA, Ay I, Ozdemir AO, Gungor IL, Togay Isikay C, et al. Assessment of safety
785 and feasibility of non-invasive vagus nerve stimulation for treatment of acute stroke. *Brain Stimul.*
786 2022;15: 1467–1474. doi:10.1016/j.brs.2022.10.012

- 787 59. Drewes AM, Brock C, Rasmussen SE, Møller HJ, Brock B, Deleuran BW, et al. Short-term
788 transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-
789 inflammatory cytokines in rheumatoid arthritis: results of a pilot study. *Scand J Rheumatol.* 2021;50:
790 20–27. doi:10.1080/03009742.2020.1764617
- 791 60. Lerman I, Hauger R, Sorkin L, Proudfoot J, Davis B, Huang A, et al. Noninvasive Transcutaneous
792 Vagus Nerve Stimulation Decreases Whole Blood Culture-Derived Cytokines and Chemokines: A
793 Randomized, Blinded, Healthy Control Pilot Trial. *Neuromodulation.* John Wiley & Sons, Ltd; 2016;19:
794 283–290. doi:10.1111/ner.12398
- 795 61. Addorasio ME, Imperato GH, de Vos AF, Forti S, Goldstein RS, Pavlov VA, et al. Investigational
796 treatment of rheumatoid arthritis with a vibrotactile device applied to the external ear. *Bioelectron*
797 *Med.* BioMed Central; 2019;5: 4–11. doi:10.1186/s42234-019-0020-4
- 798 62. Howland RH. Vagus Nerve Stimulation. *Curr Behav Neurosci Rep.* 2014;1: 64–73.
799 doi:10.1007/s40473-014-0010-5
- 800 63. Jongkees BJ, Immink MA, Finisguerra A, Colzato LS. Transcutaneous Vagus Nerve Stimulation
801 (tVNS) Enhances Response Selection During Sequential Action. *Front Psychol.* Frontiers; 2018;9:
802 1159. doi:10.3389/fpsyg.2018.01159
- 803 64. Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical Review of
804 Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical Practice. *Front*
805 *Neurosci.* 2020;14: 284. doi:10.3389/fnins.2020.00284
- 806 65. Rodríguez García PL, Rodríguez Pupo LR, Rodríguez García D. [Diagnosis of delayed cerebral
807 ischaemia and cerebral vasospasm in subarachnoid haemorrhage]. *Neurologia.* 2010;25: 322–330.
- 808 66. Athiraman U, Aum D, Vellimana AK, Osburn JW, Dhar R, Tempelhoff R, et al. Evidence for a
809 conditioning effect of inhalational anesthetics on angiographic vasospasm after aneurysmal
810 subarachnoid hemorrhage. *J Neurosurg.* 2019;; 1–7. doi:10.3171/2019.3.JNS183512

- 811 67. Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, et al. Vagus nerve
812 stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc
813 Natl Acad Sci USA. 2016;113: 8284–8289. doi:10.1073/pnas.1605635113
- 814 68. Rosner BA. Fundamentals of Biostatistics. Thomson Brooks/Cole; 2000.
- 815 69. Brown H, Prescott R. Applied Mixed Models in Medicine. John Wiley & Sons; 2015.
- 816 70. Liu H, Wu T. Sample Size Calculation and Power Analysis of Time-Averaged Difference. Journal of
817 Modern Applied Statistical Methods. 2005;4: 434–435. doi:10.22237/jmasm/1130803680
- 818 71. Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of Longitudinal Data. OUP Oxford; 2013.
- 819

	STUDY PERIOD						
	Enrollment	Allocation	Post-allocation				Close-out
TIMEPOINT	Pre-randomization	Before Initiation of Intervention	Baseline	During ICU Stay	Post-ICU Stay	Discharge	Follow-up up to 2 years after discharge
ENROLLMENT							
Eligibility screen	X						
Informed consent	X						
Randomization		X					
Allocation		X					
INTERVENTIONS							
taVNS group				X			
Sham group				X			
ASSESSMENTS							
Plasma collected			X	X	X	X	
CSF collected			X	X			
mRS Assessed			X			X	X

Patient in the Intensive Care Unit

Patient on Neurosurgical Floor

Patient Outpatient

Enrolled
within 24
hours of
admission

Treatment arm: Auricular VNS twice daily (AM and PM session)
Control arm: Sham stimulation without current twice daily (AM and PM session)

Treatments Complete

Discharge

Modified Rankin Scale
Documented at each
follow up

Day 1

Day 4

Day 7

Day $n+3$

...+3 days

...+3 days

...+3 days

...+3 days

Variable

2 years




Blood collected



CSF collected (if external ventricular drain in place)

medRxiv preprint doi: <https://doi.org/10.1101/2024.03.19.24304239>; this version posted March 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Auricular Branch of the Vagus Nerve